Inhibition of HDAC utilising panobinostat in combination with bortezomib and dexamethasone (PANORAMA2)12 or vorinostat in combination with bortezomib (VANTAGE)7 has been shown to be effective in patients with relapsed refractory myeloma, particularly in high‐risk subgroups. Here, HDAC9 is linked to plasma cell myeloma.